



Alan Wovsaniker

Partner

New Jersey

T: +1 973.597.2564 | F: +1 973.597.2565

awovsaniker@lowenstein.com

Alan has more than 40 years of experience handling mergers and acquisitions, securities offerings, corporate finance and governance, securities compliance, financial restructurings, and general corporate matters. A significant portion of Alan's practice is focused on helping biotechnology companies gain the resources they need to invent, prove, and market new ways to enhance human health.

An "excellent lawyer" (*Chambers*), Alan provides his clients with comprehensive support across their companies' life cycles, whether he is acting as day-to-day legal counsel or as a key strategist for raising capital, acquiring assets and capabilities, complying with legal and regulatory requirements, or selling the business. He also helps clients restructure or sell companies that are in bankruptcy.

EXPERIENCE

- > We are representing Aravive Biologics, Inc., as co-counsel, in its pending merger with a wholly owned subsidiary of Versartis, Inc. (Nasdaq:VSAR) in an all-stock transaction.
- > Represented Cancer Genetics Inc. in its initial public offering in 2013 as well as seven follow-on offerings through 2017, raising over \$100 million.
- > Represented Cancer Genetics Inc. in the acquisition of BioServe India, Gentris, LLC, Response Genetics, Inc., and *vivo*Pharm Pty. Ltd. (Australia).
- > Represented NeoStem Inc. in connection with over 10 public offerings from 2007 to 2014, raising over \$150 million, as well as in various private securities offerings.
- > Represented NeoStem Inc. in its entry into the stem cell business and its acquisitions of California Stem Cell Inc., Progenitor Cell Therapy, and Amorcyte, as well as its acquisition and disposition of Suzhou Erye, a Chinese pharmaceutical manufacturer.
- > Represented Celldex Therapeutics in its \$200 million public offering in 2015 and \$103 million public offering in 2013.
- > Represented LifeCell Corporation for 10 years, culminating in its 2008 sale to Kinetic Concepts Inc. for \$1.8 billion.
- > Represented MiaMed Inc. in its 2016 sale to Amicus Therapeutics (Nasdaq: FOLD) for up to \$90 million.
- > Represented Dance Biopharm in connection with \$20 million of private financing in 2015 toward development of an inhaled insulin system.
- > Represented Metalico Inc. in its sale for \$102 million to Total Merchant Limited.
- > Served as outside general counsel for Consolidated Delivery & Logistics from the company's 1995 IPO and acquisition of 25 delivery and logistics companies through its sale to Velocity Express Corporation.
- > Represented Velocity Express Corporation in the 2009 restructuring of the company's \$100 million mezzanine debt facility through a sale to its lender in a prepackaged bankruptcy proceeding.
- > Represented Cerberus Capital Management in its \$1.1 billion acquisition out of bankruptcy of Tower Automotive in 2007.
- > Represented The Newark Group in multiple acquisitions, plus its \$175 million offering of senior subordinated notes in 2004.
- > Represented Vestcom in its IPO and simultaneous acquisition of seven private companies.

HONORS & AWARDS

- > **Chambers USA: America's Leading Lawyers for Business (2003-2020)**
Featured annually as a top leader since the guide's 2003 inception
Recognized for work in Corporate/M&A
- > **The Best Lawyers in America (2018, 2020)**
Ranked as 2018 and 2020 Lawyer of the Year in the Mergers & Acquisitions section.

- > **The Best Lawyers in America (2005-2020)**
Recognized in the Corporate Law, Mergers & Acquisitions Law, and Securities / Capital Markets Law sections.
- > **New Jersey Super Lawyers (2005-2010, 2012-2014)**

NEWS & INSIGHTS

Publications

- > February 27, 2019
"SEC Proposes Expansion of "Test-the-Waters" Communications to All Issuers," *Capital Markets & Securities Client Alert*
Alan Wovsaniker, Daniel C. Porco
- > January 4, 2019
"SEC Adopts Compensation Hedging Disclosure Rule," *Capital Markets & Securities Client Alert*
Alan Wovsaniker, Claudia Lorenzo, Daniel C. Porco
- > October 11, 2018
"SEC Approves Changes to Nasdaq Shareholder Approval Rules," *Capital Markets & Securities Client Alert*
Alan Wovsaniker
- > October 11, 2018
"Obstacles to IPOs faced by life sciences companies," *The Pharma Letter*
Alan Wovsaniker
- > July 2, 2018
"How Regulation A Updates Could Benefit Smaller Reporting Companies," *Corporate Counsel*
John D. "Jack" Hogoboom, Alan Wovsaniker, Alexander Dinur
- > June 5, 2018
"Regulation A Availability for Securities Offerings by Smaller Reporting Companies," *Capital Markets & Securities Client Alert*
Alexander Dinur, Alan Wovsaniker, John D. "Jack" Hogoboom
- > September 26, 2017
"SEC Provides Interpretive Guidance on Pay Ratio Rule," *Capital Markets & Securities Client Alert*
Steven M. Skolnick, Peter H. Ehrenberg, John D. "Jack" Hogoboom, , Alan Wovsaniker
- > June 30, 2017
"SEC Expands Use of Confidential IPO Filings," *Capital Markets & Securities Client Alert*
Alan Wovsaniker, John D. "Jack" Hogoboom
- > April 13, 2017
"SEC Issues Statement on Conflict Minerals Rule; Not Much Changes," *Capital Markets & Securities Client Alert*
Peter H. Ehrenberg, Steven M. Skolnick, John D. "Jack" Hogoboom, Alan Wovsaniker
- > March 23, 2017
"SEC Shortens Settlement Cycle from T+3 to T+2," *Capital Markets & Securities Client Alert*
Peter H. Ehrenberg, Steven M. Skolnick, John D. "Jack" Hogoboom, , Alan Wovsaniker
- > March 2, 2017
"SEC to Require Hyperlinks to Exhibits," *Capital Markets & Securities Client Alert*
John D. "Jack" Hogoboom, Steven M. Skolnick, Alan Wovsaniker
- > February 21, 2017
"Sparking Discussion and Adding Fuel to the Fire: FDA Discussion Paper on Laboratory Developed Tests (LDTs)," *Life Sciences Client Alert*
James C. Shehan, Alan Wovsaniker
- > 2016
"The JOBS Act: Improving Access to Capital Markets for Smaller Businesses," *Recent Developments in Securities Law*
Steven M. Skolnick, Alan Wovsaniker, Steven E. Siesser

In the Media

- > June 22, 2020
Lowenstein's representation of issuer **Celldex Therapeutics, Inc.** (Celldex) (Nasdaq: CLDX) in connection with the company's approximately \$150 million public offering of common stock is highlighted in the **Global Legal Chronicle**. The Lowenstein team included **Anthony O. Pergola, Alan Wovsaniker, Kate Basmagian, Alexander Dinur, Madeline Roe, Sarah Gore,** and **Robert J. Paradiso**. **View Lowenstein's news announcement about this transaction.**
- > June 11; June 15, 2020
ROI-NJ, citybizlist, S&P Global, InvestorsHub, MarketScreener.com, and the **Global Legal Chronicle** report that Lowenstein client DelMar Pharmaceuticals, Inc. (Nasdaq: DMPPI),

a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero Biopharmaceuticals Holdings, Inc., a privately held biopharmaceutical company focused on the development of its late stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. The Lowenstein deal team includes **Michael J. Lerner, Steven M. Skolnick, Alan Wovsaniker, Kate Basmagian, Robert Bee, Justin Gindi, and Erica Perlmutter.** [View Lowenstein's news announcement about this transaction.](#)

> January 29, 2020

Lowenstein's representation of **Timber Pharmaceuticals** in its definitive merger agreement with BioPharmX Corporation was noted in **citybizlist, ROI-NJ, BioWorld, and Cision PR Newswire.** The Lowenstein deal team included **Steven M. Skolnick, Alan Wovsaniker, Alexander Dinur, and Tracy F. Buffer.** [View Lowenstein's news announcement about this transaction.](#)

> September 23-27, 2019; December 19, 2019

Lowenstein's role representing Arotech Corporation (ARTX) in its agreement to be acquired for approximately \$80.8 million is mentioned in **The Deal, Law360 (September 23, 2019; September 27, 2019), the Global Legal Chronicle, GlobeNewswire, Crain's Detroit Business, Yahoo Finance, and Nasdaq.** The Lowenstein deal team included **Steven M. Skolnick, Alan Wovsaniker, Kate Basmagian, Elisia M. Klinka, and Mitchell McDonald.** *(subscription required to access certain content)* [View Lowenstein's news announcement about this transaction.](#)

> June 4, 2018

4-traders.com and **StreetInsider.com** note Lowenstein Sandler as legal co-counsel with Gracin & Marlow, LLP to **Aravive Biologics, Inc.** in connection with its merger with a wholly owned subsidiary of **Versartis, Inc.** in an all-stock transaction. (Lowenstein deal team: **Alan Wovsaniker** and **Andrew E. Graw.**)

SPEAKING ENGAGEMENTS

> Speaker, **Americas Growth Intelligence Forum**, Global M&A Network, New York, NY, October 24, 2019

EDUCATION

> Harvard Law School (J.D. 1977), magna cum laude

> Brown University (A.B. 1974), magna cum laude; Phi Beta Kappa

ADMISSIONS

> New Jersey